| Literature DB >> 29764230 |
Byron Creese1, Miguel Vasconcelos Da Silva1, Iskandar Johar2, Clive Ballard1.
Abstract
INTRODUCTION: Antipsychotics have long been the mainstay of treatment for agitation and psychosis in Alzheimer's disease. Despite their current use successive studies have shown that they only confer a modest benefit which must be balanced against their well-established serious side effects (extrapyramidal symptoms, stroke, accelerated cognitive decline and mortality). Areas covered: This review outlines the current guidance on antipsychotic usage and the evidence of their continued usage against a backdrop of emerging pharmacological treatments and an increasing emphasis on the importance of non-pharmacological interventions. Expert commentary: The current justification for antipsychotic use in the context of the changing landscape of prescribing and provide a view on the most promising alternative candidates to this class of drug are appraised.Entities:
Keywords: Agitation; Alzheimer’s disease; atypical antipsychotics; dementia; psychosis
Mesh:
Substances:
Year: 2018 PMID: 29764230 DOI: 10.1080/14737175.2018.1476140
Source DB: PubMed Journal: Expert Rev Neurother ISSN: 1473-7175 Impact factor: 4.618